216 related articles for article (PubMed ID: 30112725)
1. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
Landy S; Munjal S; Brand-Schieber E; Rapoport AM
J Headache Pain; 2018 Aug; 19(1):70. PubMed ID: 30112725
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.
Landy S; Munjal S; Brand-Schieber E; Rapoport AM
J Headache Pain; 2018 Aug; 19(1):69. PubMed ID: 30112726
[TBL] [Abstract][Full Text] [Related]
3. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine.
Cady RK; Munjal S; Cady RJ; Manley HR; Brand-Schieber E
J Headache Pain; 2017 Dec; 18(1):17. PubMed ID: 28176235
[TBL] [Abstract][Full Text] [Related]
5. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
Munjal S; Brand-Schieber E; Allenby K; Spierings ELH; Cady RK; Rapoport AM
J Headache Pain; 2017 Dec; 18(1):31. PubMed ID: 28251391
[TBL] [Abstract][Full Text] [Related]
7. DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
CNS Drugs; 2019 Apr; 33(4):375-382. PubMed ID: 30877622
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Tepper SJ; Dodick DW
Headache; 2020 Jan; 60(1):58-70. PubMed ID: 31647577
[TBL] [Abstract][Full Text] [Related]
10. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
[TBL] [Abstract][Full Text] [Related]
11. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan.
Landy SH; Tepper SJ; Wein T; Schweizer E; Ramos E
Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799
[TBL] [Abstract][Full Text] [Related]
12. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
[TBL] [Abstract][Full Text] [Related]
14. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults.
Derry CJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD009665. PubMed ID: 22336869
[TBL] [Abstract][Full Text] [Related]
15. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
16. Sumatriptan (oral route of administration) for acute migraine attacks in adults.
Derry CJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008615. PubMed ID: 22336849
[TBL] [Abstract][Full Text] [Related]
17. Long-term evaluation of sumatriptan and naproxen sodium for the acute treatment of migraine in adolescents.
McDonald SA; Hershey AD; Pearlman E; Lewis D; Winner PK; Rothner D; Linder SL; Runken MC; Richard NE; Derosier FJ
Headache; 2011 Oct; 51(9):1374-87. PubMed ID: 21797863
[TBL] [Abstract][Full Text] [Related]
18. Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine.
Peikert A; Becker WJ; Ashford EA; Dahlof C; Hassani H; Salonen RJ
Eur J Neurol; 1999 Jan; 6(1):43-9. PubMed ID: 10209349
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group.
Diener HC
Cephalalgia; 1999 Jul; 19(6):581-8; discussion 542. PubMed ID: 10448545
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets.
Savani N; Pfaffenrath V; Rice L; Boswell D; Black L; Jones M;
Clin Ther; 2001 Feb; 23(2):260-71. PubMed ID: 11293559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
